← All Centessa Pharmaceuticals PLC filings

Centessa Pharmaceuticals PLC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CNTA
Centessa Pharmaceuticals PLC
DEF: Centessa Pharmaceuticals PLC Annual General Meeting Notice
Centessa Pharmaceuticals PLC has issued a proxy statement for its 2026 Annual General Meeting, scheduled for June 12, 2026, detailing proposals for director re-appointments, auditor ratification, and adoption of financial reports.
NASDAQ
CNTA
Centessa Pharmaceuticals PLC
DEFA14A: Centessa Pharmaceuticals Advances Key Pipeline Programs, Extends Cash Runway into 2027 Amid Strategic Portfolio Shifts
Centessa Pharmaceuticals PLC announced its 2024 annual results, highlighting significant progress in its orexin receptor 2 (OX2R) agonist pipeline, an extended cash runway into 2027, and a new licensing deal, alongside strategic discontinuations of other development programs.
NASDAQ
CNTA
Centessa Pharmaceuticals PLC
DEF: Centessa Pharmaceuticals Seeks Shareholder Approval for Director Re-elections and Remuneration Policies at 2025 AGM
Centessa Pharmaceuticals is holding its Annual General Meeting on June 20, 2025, seeking shareholder approval for director re-elections, auditor appointments, and remuneration policies.
NASDAQ
CNTA
Centessa Pharmaceuticals PLC
DEFA14A: Centessa Pharmaceuticals PLC Reports Progress in Pipeline Programs and Financial Results for Year Ended December 31, 2023
Centessa Pharmaceuticals PLC highlights advancements in its pipeline programs, including SerpinPC and ORX750, while reporting its financial results for the year ended December 31, 2023.
NASDAQ
CNTA
Centessa Pharmaceuticals PLC
DEF 14A: Centessa Pharmaceuticals Sets Date for 2024 Annual General Meeting, Outlines Key Proposals
Centessa Pharmaceuticals announces its 2024 Annual General Meeting (AGM) to be held on June 25, 2024, in London, detailing resolutions for shareholder voting including director re-appointments, auditor ratification, and share allotment authorizations.